Physician profile
Michael C Harper
NPI 1487615415
$2,488.08
in general payments reported to CMS, 2019-2025
31 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $139 · 2021: $548 · 2022: $414 · 2023: $434 · 2024: $384 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $342.99 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $247.05 | 2021-2023 | |
| Glaxosmithkline, LLC. | $205.33 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $185.86 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $178.84 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Amarin Pharma, INC. | $142.96 | 2019-2022 | |
| Mylan Specialty L.P. | $140.18 | 2019-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $119.48 | 2019-2024 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $117.73 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.62 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $99.04 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $83.63 | 2019-2021 | |
| Esperion Therapeutics, INC. | $66.46 | 2021 | |
| Abbvie INC. | $59.16 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $48.51 | 2023 | Gemtesa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $47.50 | 2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $35.99 | 2022 | |
| Merck Sharp & Dohme LLC | $33.12 | 2021-2023 | Vaxneuvance, Pneumovax 23, Vaxelis |
| Abbott Laboratories | $30.01 | 2022-2024 | Freestyle Libre |
| Seqirus USA INC | $29.54 | 2019-2025 | Flucelvax |
| Abiomed | $29.20 | 2025 | |
| Xeris Pharmaceuticals, INC. | $23.83 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.04 | 2022 | |
| Medtronic Vascular, INC. | $18.80 | 2020 | |
| Medtronic, INC. | $18.21 | 2025 | Minimed 780g |
| Dexcom, INC. | $16.69 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.41 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $12.58 | 2021 | |
| Allergan, INC. | $11.32 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.